HomeAI · summaries
Storia in 5 fonti
Vera's IgAN approval kicks off competition with Otsuka
Vera Therapeutics' atacicept wins FDA accelerated approval for IgAN, entering a competitive market alongside Otsuka's Voyxact with a dual APRIL/BAFF mechanism.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
What's Going on with Vera Therapeutics Stock on Monday? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors weigh trial data and competition from Novartis.
- ·
healio.com
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to…
- ·
fiercepharma.com
FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no FDA-approved treatment options. | When Vera…
- ·
statnews.com
FDA approves Vera Therapeutics kidney disease treatment
The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
- ·
endpoints.news
Vera's IgAN approval kicks off competition with Otsuka
Vera Therapeutics' atacicept wins FDA accelerated approval for IgAN, entering a competitive market alongside Otsuka's Voyxact with a dual APRIL/BAFF mechanism.
- ·
Why Is Vera Therapeutics Stock Gaining Tuesday? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease drug Trutakna. Full analysis here.